Caroline Dive

Cancer Research UK Manchester Institute — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

98h-index45.8kcitations899works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(161), Lung Cancer Research Studies(103), Cancer Cells and Metastasis(95), Lung Cancer Treatments and Mutations(79), Cell death mechanisms and regulation(70)

Publications874 total

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint Blockade
Cancer Discovery·2026Open Access
Table S1 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
2026Open Access
Figure S9 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
2026Open Access
Table S4 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
2026Open Access
Figure S11 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
2026Open Access
Figure S3 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
2026Open Access
Small-cell lung cancer: anatomy of an immune-cold tumor
Trends in cancer·2025
UpSMART: five years of digital innovation in cancer clinical research—achievements, challenges, and recommendations
Frontiers in Digital Health·2025Open Access
Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Figure S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Table S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Figure S4. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Figure S1. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study
Clinical Colorectal Cancer·2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
European Journal of Cancer·2025
Abstract IA03: A Tale of Two Biomarkers: Improving Outcomes for Cancer of Unknown Primary and Recurrent Early Stage Non-Small Cell Lung Cancer
Molecular Cancer Therapeutics·2025
Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Cancer Discovery·2025· 1 citedOpen Access
Studying a human genetic model of lung squamous cell carcinoma with organotypic cultures and xenografts uncovers distinct advantages of each system and implicates NOTCH1 loss in tumour development
2025Open Access
173TiP DyNAMIc trial: Circulating tumour DNA guided adaptive BRAF and MEK inhibitor therapy - A phase II randomised proof of concept study
Annals of Oncology·2025
1151P Plasma Tie2 is a valid biomarker for VEGF inhibitors (VEGFi) in endometrial cancer: Evidence from the COPELIA three-arm randomised controlled trial (RCT)
Annals of Oncology·2025Open Access
page 1 of 44Next →

Frequent Co-authors

Fiona Blackhall(17), Matthew Krebs(12), Ged Brady(9), Lynsey Priest(8), Andrew Hughes(8), Dominic G. Rothwell(8), Tim Ward(6), Crispin Miller(6), Nicolai J. Birkbak(5), Selvaraju Veeriah(5), Sophia Ward(5), Yvonne Summers(5), Philip Crosbie(5), John Le Quesne(5), Robert Szczepaniak‐Sloane(5), Malcolm Ranson(5), Daisuke Nonaka(5), Mariam Jamal‐Hanjani(4), Gareth A. Wilson(4), Nicholas McGranahan(4)